This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Shizuoka Prefecture, Taiho Pharmaceutical Company Limited. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 15 
1 out of 320 
Years Active: 2013
Title: The Innovative Contributions of Sung Hwa Park
Introduction
Sung Hwa Park is a notable inventor based in Shizuoka, Japan. He has made significant contributions to the field of cancer treatment through his innovative patent. His work focuses on developing effective antitumor agents that can enhance the treatment of cancer in mammals.
Latest Patents
Sung Hwa Park holds a patent for an antitumor agent, kit, and method of treating cancer. The patent discloses an antitumor preparation that comprises a combination of a drug consisting of tegafur, gimeracil, and oteracil potassium, along with folinic acid and cis-oxalate(1R,2R-diaminocyclohexane)platinum(II). This combination aims to enhance the antitumor effects and provides a comprehensive method for treating cancer.
Career Highlights
Throughout his career, Sung Hwa Park has worked with prominent organizations, including the Shizuoka Prefecture and Taiho Pharmaceutical Company Limited. His experience in these institutions has contributed to his expertise in pharmaceutical innovations and cancer treatment.
Collaborations
Due to space constraints, the collaborations section will be omitted.
Conclusion
Sung Hwa Park's contributions to cancer treatment through his innovative patent demonstrate his commitment to advancing medical science. His work continues to inspire future research and development in the field of oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile